## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($92.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. Boston Scientific (BSX) Stock After Hours on Dec. 24, 2025: Key Moves, Today’s Fresh Analysis, and What to Watch Before Markets Reopen**
- Source: ts2.tech | 20251225T030820 | Somewhat-Bullish | Relevance: 100%
- Boston Scientific (NYSE: BSX) experienced a modest uptick in after-hours trading on Christmas Eve, closing at $96.13 in regular trading and $96.38 after hours. With markets closed on Christmas Day, investors are analyzing recent commentary focusing on the company's strong Endoscopy business and ongoing debate about its valuation, despite strong fundamental growth. Analysts maintain a "Buy" consensus with price targets significantly above the current trading price.

**2. Does Boston Scientific’s Strong Run Match Its Current Valuation in 2025?**
- Source: Simply Wall Street | 20251225T030805 | Bearish | Relevance: 100%
- Boston Scientific has seen significant stock gains over the past few years, driven by innovation in its cardiovascular and minimally invasive device portfolio. However, current analyses suggest the company may be overvalued. Both Discounted Cash Flow and Price-to-Earnings ratios indicate that Boston Scientific's market price exceeds its intrinsic value and typical industry multiples.

**3. VCI Wealth Management LLC Invests $1.26 Million in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251226T115347 | Bullish | Relevance: 100%
- VCI Wealth Management LLC has acquired a new stake of 12,885 shares in Boston Scientific Corporation, valued at approximately $1.26 million. This investment comes despite recent insider selling, with corporate insiders divesting 143,095 shares worth about $14.23 million in the last 90 days. Wall Street analysts generally hold a "Buy" rating for Boston Scientific, with a consensus price target of $124.85, following the company's Q3 earnings beat and positive FY2025 EPS guidance.

**4. Boston Scientific Corporation $BSX Shares Acquired by Brookstone Capital Management**
- Source: MarketBeat | 20251226T085100 | Bullish | Relevance: 100%
- Brookstone Capital Management increased its stake in Boston Scientific ($BSX) by 12.0% in Q3, now holding 129,321 shares valued at $12.63 million. Institutional investors own approximately 89.07% of the company, with Vanguard and State Street as major holders. Boston Scientific reported Q3 EPS of $0.75, exceeding estimates, and set FY2025 EPS guidance between $3.020 and $3.040, maintaining a consensus "Buy" rating from analysts with an average price target of $124.85.

**5. Exchange Traded Concepts LLC Boosts Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251224T220808 | Bullish | Relevance: 100%
- Exchange Traded Concepts LLC significantly increased its stake in Boston Scientific Corporation, purchasing an additional 22,791 shares to hold a total of 64,663 shares valued at approximately $6.313 million. This increase reflects growing institutional interest in Boston Scientific, which recently beat Q3 earnings estimates with EPS of $0.75 and revenue of $5.07 billion. Despite significant insider selling over the past 90 days, institutional investors hold 89.07% of the stock, and analysts maintain a consensus "Buy" rating with an average target price of $124.85.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.4B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 27.7 |
| Current P/E | 31.7 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -0.2% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 48. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.16% (CS: 70) | Neutral |
| RSI_14 | 48.5 | Neutral |
| MACD Histogram | 0.40 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.975x | Below |
| vs SMA200 | 0.952x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.08
- **Stop Loss:** $92.32 (3.9% risk)
- **Target:** $99.84 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 351
- **Position Value:** $33,724.08
- **Portfolio %:** 33.72%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*